Abstracts tagged "Anti-TNF therapy and spondylarthritis"

Abstract Number: 1545 • 2017 ACR/ARHP Annual Meeting
Evaluation of the Adherence to Recommendations for Tnfα Blockers Use and Its Impact over 5 Years of Follow-up in Early Axial Spondyloarthritis. Data from the DESIR Cohort
Clementina López-Medina^1,2, Maxime Dougados³, Eduardo Collantes-Estévez⁴ and Anna Molto⁵, ¹Rheumatology Department, Reina Sofía University Hospital/ Maimonides Institute for Biomedical Research of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, ²Rheumatology Department, Cochin Hospital, Paris, France, ³Hôpital Cochin, Paris, France, ⁴Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁵Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France
Background/Purpose: Several recommendations have been published for the use of TNFα blockers (TNFb) in patients with axial Spondyloarthritis (axSpA). However, there is only sparse data…
Abstract Number: 1747 • 2015 ACR/ARHP Annual Meeting
Predictors of Survival on Anti-TNF in an Observational Cohort of Patients with Ankylosing Spondylitis: The Role of MRI Parameters of Inflammation and Structural Damage
Walter Maksymowych¹, Zheng Zhao², Stephanie Wichuk¹, Praveena Chiowchanwisawakit³, Robert G Lambert⁴, Sasha Bernatsky⁵, Barbara Conner-Spady¹, Donald Spady¹ and Susanne Juhl Pedersen⁶, ¹Medicine, Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, Chinese PLA General Hospital, Beijing, China, ³Rheumatology, Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand, ⁴Radiology, Radiology, University of Alberta, Edmonton, AB, Canada, ⁵Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ⁶Copenhagen Center for Arthritis Research, Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: There has been no data reported evaluating MRI parameters of inflammation and structural damage. We aimed to identify factors influencing survival on anti-TNF therapy…
Abstract Number: 2863 • 2015 ACR/ARHP Annual Meeting
Discontinuation of Anti-TNF Therapy in Patients with Axial Spondyloarthritis. a Systematic Literature Review
Victoria Navarro-Compán¹, Chamaida Plasencia-Rodriguez², Eugenio De Miguel¹, Alejandro Balsa³, Emilio Martín-Mola¹, Daniel Seoane-Mato⁴ and Juan D. Cañete⁵, ¹Rheumatology, University Hospital La Paz, Madrid, Spain, ²Rheumatology Department, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ³Rheumatology, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ⁴Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ⁵Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain
Background/Purpose: In patients with axial spondyloarthritis (axSpA), anti-TNF therapy is successful for clinically improving signs and symptoms of the disease. However, there is no clear…
Abstract Number: 2554 • 2014 ACR/ARHP Annual Meeting
Do TNF Alpha Inhibitors Have an NSAID Sparing Effect in Real Life in Early Axial Spa? Results from the DESIR Cohort
Anna Moltó^1,2, Benjamin Granger³, Daniel Wendling⁴, Maxime A. Breban⁵, Maxime Dougados⁶ and Laure Gossec⁷, ¹GRC-UPMC 08 (EEMOIS); UPMC Univ Paris 06.AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France., Paris, France, ²Paris Descartes University, Rheumatology Department, Cochin Hospital, AP-HP. INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ³Biostatistics - GRC08-EEMOIS, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, ⁴Service de Rhumatologie, CHU J Minjoz, Besancon, France, ⁵Rheumatology, Ambroise Paré Hospital, and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁶INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ⁷Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are the keystone in the treatment of axial Spondyloarthritis (axSpA), but have potential side effects (cardiovascular and gastrointestinal). Effectiveness of…
Abstract Number: 598 • 2014 ACR/ARHP Annual Meeting
Anti-Drug Antibodies As a Predictor for the Discontinuation of Anti-TNF Agents in Patients with Spondyloarthrtis
Jiwon Hwang¹, In young Kim¹, Seulkee Lee¹, Hyemin Jeong¹, Hyungjin Kim¹, Jaejoon Lee², Eun-mi Koh² and Hoon-Suk Cha¹, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Division of Rheumatology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose : Tumor necrosis factor (TNF) blocking agent has shown to be effective in patients with axial spondyloarthritis (SpA) including ankylosing spondylitis (AS) as up…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].